Table 2.
Univariate analysis of prognostic factors in NPC patients
| Characteristics | 3-year OS | 3-year LRFS | 3-year DMFS | |||||
|---|---|---|---|---|---|---|---|---|
| HR(95%CI) | p-Value | HR(95%CI) | p-Value | HR(95%CI) | p-Value | |||
| Sex | ||||||||
| Male | Reference | Reference | Reference | |||||
| Female | 0.944(0.366–2.434) | 0.906 | 2.502(1.041–6.011) | 0.040 | 0.998(0.437–2.280) | 0.997 | ||
| Age(years) | ||||||||
| < 46 | Reference | Reference | Reference | |||||
| ≥ 46 | 5.221(1.538–17.726) | 0.008 | 2.583(0.938–7.108) | 0.066 | 2.023(0.777–5.266) | 0.149 | ||
| T stage | ||||||||
| T1-2 | Reference | Reference | Reference | |||||
| T3 | 1.145(0.323–4.058) | 0.834 | 1.398(0.464–4.171) | 0.548 | 1.406(0.502–3.802) | 0.502 | ||
| T4 | 2.354(0.750–7.394) | 0.143 | 1.009(0.308–3.307) | 0.988 | 1.447(0.526–3.983) | 0.472 | ||
| N stage | ||||||||
| N0-N1 | Reference | Reference | Reference | |||||
| N2 | 2.298(0.698–7.632) | 0.174 | 1.890(0.618–5.777) | 0.264 | 1.284(0.522–3.160) | 0.586 | ||
| N3 | 6.365(1.959–20.678) | 0.002 | 4.048(1.284–12.765) | 0.017 | 2.548(0.982–6.610) | 0.054 | ||
| Histology type | ||||||||
| II | Reference | Reference | Reference | |||||
| III | 1.183(0.159–8.813) | 0.870 | 0.319(0.094–1.091) | 0.069 | 0.306(0.106–0.885) | 0.029 | ||
| Smoking | ||||||||
| No | Reference | Reference | Reference | |||||
| Yes | 1.528(0.649–3.597) | 0.332 | 0.875(0.349–2.194) | 0.776 | 1.356(0.635–2.897) | 0.432 | ||
| Family history | ||||||||
| No | Reference | Reference | Reference | |||||
| Yes | 0.043(0.000-37.654) | 0.363 | 0.043(0.000-41.142) | 0.370 | 0.043(0.000-15.312) | 0.294 | ||
| Treatment | ||||||||
| IMRT | Reference | Reference | Reference | |||||
| CCRT | 1.823(0.233–14.242) | 0.567 | 2.418(0.316–18.486) | 0.395 | 2.826(0.373–21.394) | 0.314 | ||
| CCRT + IC/AC | 1.943(0.249–15.177) | 0.527 | 1.152(0.139–9.570) | 0.896 | 2.152(0.278–16.670) | 0.463 | ||
| EBV DNA-PLR | ||||||||
| LRG (0 point) | Reference | Reference | Reference | |||||
| MRG (1 point) | 4.924(1.064–22.792) | 0.041 | 2.792(0.876–8.904) | 0.083 | 1.885(0.742–4.789) | 0.183 | ||
| HRG (2 point) | 19.867(4.349–90.752) | < 0.001 | 5.985(1.687–21.230) | 0.006 | 4.503(1.632–12.429) | 0.004 | ||
Notes: Bold indicates statistically significant with p < 0.2
Abbreviations: IMRT, intensity-modulated radiotherapy; CCRT, concurrent chemoradiotherapy; IC, induction chemotherapy; AC, adjuvant chemotherapy; LRG, low risk group; MRG, medium risk group; HRG, high risk group. EBV, Epstein-Barr virus; PLR, platelet-to-lymphocyte ratio; OS, overall survival; LRFS, local recurrence-free survival; DMFS, distant metastasis-free survival; HR, hazard ratio; CI, confidence interval